WO2005003147A3 - Modified fluorinated nucleoside analogues - Google Patents
Modified fluorinated nucleoside analogues Download PDFInfo
- Publication number
- WO2005003147A3 WO2005003147A3 PCT/US2004/012472 US2004012472W WO2005003147A3 WO 2005003147 A3 WO2005003147 A3 WO 2005003147A3 US 2004012472 W US2004012472 W US 2004012472W WO 2005003147 A3 WO2005003147 A3 WO 2005003147A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleoside analogues
- virus
- modified fluorinated
- fluorinated nucleoside
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL19160413T PL3521297T3 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
NZ543867A NZ543867A (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
EP21216654.0A EP4032897A1 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
EP19160413.1A EP3521297B1 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
KR1020057022965A KR100883703B1 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
JP2006513231A JP4958158B2 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
PL04775900T PL1633766T3 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
MXPA05012788A MXPA05012788A (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues. |
BRPI0419345A BRPI0419345B8 (en) | 2003-05-30 | 2004-04-21 | use of (2'r)-2'-deoxy-2'-fluor-2'-c-methyl nucleoside and a pharmaceutical composition comprising it |
ES04775900T ES2726998T3 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogs |
CA2527657A CA2527657C (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
BR122018015050-5A BR122018015050B1 (en) | 2003-05-30 | 2004-04-21 | PHOSPHATE NUCLEOSIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION |
BRPI0410846A BRPI0410846B8 (en) | 2003-05-30 | 2004-04-21 | nucleoside and pharmaceutical composition comprising it |
EP04775900.6A EP1633766B1 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
SI200432464T SI1633766T1 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
AU2004253860A AU2004253860B2 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
IL172259A IL172259A (en) | 2003-05-30 | 2005-11-29 | (2'r)-2'-deoxy-2'-fluoro-2'-c-methyl nucleoside, a method of synthesizing the nucleoside and uses thereof |
NO20056221A NO333700B1 (en) | 2003-05-30 | 2005-12-28 | Modified fluorinated nucleoside analogues |
US12/878,262 US8415322B2 (en) | 2003-05-30 | 2010-09-09 | Modified fluorinated nucleoside analogues |
IL210367A IL210367A0 (en) | 2003-05-30 | 2010-12-29 | Modified fluorinated nucleoside analogues |
NO20110549A NO20110549L (en) | 2003-05-30 | 2011-04-11 | (2'R) -2'-Deoxy-2'-fluoro-2'-C-methyl nucleoside or 4E) Preparation of the same and pharmaceutical preparations comprising the nucleoside |
NO20110550A NO20110550L (en) | 2003-05-30 | 2011-04-11 | Method for inhibiting the proliferation of a Flaviviridae virus |
NO20110548A NO20110548L (en) | 2003-05-30 | 2011-04-11 | (2'R) -2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β-D or β-L) or its pharmaceutically acceptable salt |
NO20110547A NO20110547L (en) | 2003-05-30 | 2011-04-11 | Use of (2, R) -2'-deoxy-2'-fluoro-2'-C-methyl-nucleosides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47436803P | 2003-05-30 | 2003-05-30 | |
US60/474,368 | 2003-05-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/828,753 Continuation US7429572B2 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005003147A2 WO2005003147A2 (en) | 2005-01-13 |
WO2005003147A3 true WO2005003147A3 (en) | 2005-03-03 |
Family
ID=33563735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/012472 WO2005003147A2 (en) | 2003-05-30 | 2004-04-21 | Modified fluorinated nucleoside analogues |
Country Status (29)
Country | Link |
---|---|
US (8) | US7429572B2 (en) |
EP (8) | EP3521297B1 (en) |
JP (5) | JP4958158B2 (en) |
KR (1) | KR100883703B1 (en) |
CN (1) | CN100503628C (en) |
AR (6) | AR044566A1 (en) |
AU (1) | AU2004253860B2 (en) |
BR (3) | BRPI0419345B8 (en) |
CA (5) | CA2734066A1 (en) |
CO (1) | CO5660270A2 (en) |
CY (2) | CY1118020T1 (en) |
DK (1) | DK2604620T3 (en) |
ES (3) | ES2906207T3 (en) |
HR (1) | HRP20160873T1 (en) |
HU (2) | HUE029877T2 (en) |
IL (2) | IL172259A (en) |
LT (2) | LT2604620T (en) |
MX (1) | MXPA05012788A (en) |
MY (1) | MY138477A (en) |
NO (5) | NO333700B1 (en) |
NZ (1) | NZ543867A (en) |
PL (3) | PL3521297T3 (en) |
PT (3) | PT1633766T (en) |
RU (1) | RU2358979C2 (en) |
SI (3) | SI3521297T1 (en) |
TR (1) | TR201906767T4 (en) |
TW (1) | TWI333956B (en) |
WO (1) | WO2005003147A2 (en) |
ZA (1) | ZA200509521B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299038B2 (en) | 2000-05-23 | 2012-10-30 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US8957046B2 (en) | 2007-03-30 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US9045520B2 (en) | 2008-12-23 | 2015-06-02 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US9549941B2 (en) | 2011-11-29 | 2017-01-24 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
JP7196054B2 (en) | 2012-12-21 | 2022-12-26 | ヤンセン バイオファーマ インク. | Substituted Nucleosides, Substituted Nucleotides and Their Analogues |
Families Citing this family (204)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101099745A (en) * | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | Methods and compositions for treating flaviviruses and pestiviruses |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
PL374831A1 (en) * | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
CN101172993A (en) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
RS113904A (en) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
US7598373B2 (en) * | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
KR100883703B1 (en) * | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | Modified fluorinated nucleoside analogues |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
EP2348029A1 (en) * | 2004-07-21 | 2011-07-27 | Pharmasset, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
CN101023094B (en) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
SI3109244T1 (en) * | 2004-09-14 | 2019-06-28 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
AU2005317081A1 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection |
JP2008523082A (en) | 2004-12-09 | 2008-07-03 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Nucleotides having antibacterial and anticancer activities |
CN101128474A (en) | 2005-02-28 | 2008-02-20 | 健亚生物科技公司 | Tricyclic-nucleoside prodrugs for treating viral infections |
US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
AR056327A1 (en) | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
CN100478349C (en) * | 2005-06-20 | 2009-04-15 | 河南省凯特化学实业总公司 | Nucleoside fluoride compound, its production and use |
KR20080036598A (en) | 2005-08-01 | 2008-04-28 | 머크 앤드 캄파니 인코포레이티드 | Macrocyclic peptides as hcv ns3 protease inhibitors |
CN102924549A (en) * | 2005-09-26 | 2013-02-13 | 吉利德制药有限责任公司 | Modified 4'-nucleosides as antiviral agents |
UA91255C2 (en) * | 2005-12-09 | 2010-07-12 | Ф. Хоффманн-Ля Рош Аг | Antiviral nucleosides |
CA2634749C (en) * | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
KR101237312B1 (en) | 2006-02-10 | 2013-03-04 | 삼진제약주식회사 | Pharmaceutical composition for preventing or treating hepatitis c which comprises pyrimidinedione derivatives |
WO2007095269A2 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US8058260B2 (en) * | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
MX2009003795A (en) | 2006-10-10 | 2009-06-18 | Pharmasset Inc | Preparation of nucleosides ribofuranosyl pyrimidines. |
JP5513119B2 (en) * | 2006-10-19 | 2014-06-04 | シグナル ファーマシューティカルズ,エルエルシー | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
JP5345941B2 (en) | 2006-10-24 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | HCV NS3 protease inhibitor |
WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
EP2076278B1 (en) | 2006-10-24 | 2015-05-06 | Merck Sharp & Dohme Corp. | Macrocyclic HCV NS3 protease inhibitors |
US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
BRPI0718161A2 (en) | 2006-10-27 | 2013-11-26 | Merck & Co Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOUND. |
ATE542810T1 (en) * | 2006-12-18 | 2012-02-15 | Hoffmann La Roche | METHOD FOR PRODUCING 3,5-DI-OMIKRON-ACYL-2-FLUORINE-2-C-METHYL-D-RIBONO GAMMA-LACTONE |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008075103A1 (en) | 2006-12-20 | 2008-06-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
WO2008079206A1 (en) * | 2006-12-20 | 2008-07-03 | Merck & Co., Inc. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US8071568B2 (en) * | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
WO2008090046A1 (en) * | 2007-01-23 | 2008-07-31 | F. Hoffmann-La Roche Ag | Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
AU2008219622A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors |
AU2014233579B2 (en) * | 2007-03-30 | 2016-06-23 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
CN100532388C (en) * | 2007-07-16 | 2009-08-26 | 郑州大学 | 2'-fluorine-4'-substituted-nucleosides analog, preparation method and uses thereof |
EP2178886A1 (en) | 2007-07-17 | 2010-04-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
US20100305060A1 (en) * | 2007-11-29 | 2010-12-02 | Ligand Pharmaceuticals Incorporated | Nucleoside Prodrugs and Uses Thereof |
US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CN102177172A (en) | 2008-07-02 | 2011-09-07 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
DK2540350T3 (en) | 2008-07-22 | 2014-08-04 | Merck Sharp & Dohme | COMBINATIONS OF A MACROCYCLIC QUINOXAL COMPOUND, WHICH IS ANHCV-NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS |
NZ617066A (en) * | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
CA2748057C (en) * | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
JP2012514606A (en) * | 2009-01-07 | 2012-06-28 | サイネクシス,インコーポレーテッド | Formulation of cyclosporine derivatives and nucleosides for the treatment of HCV |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
AR075584A1 (en) * | 2009-02-27 | 2011-04-20 | Intermune Inc | THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND. |
EP2403860B1 (en) | 2009-03-04 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole as hcv polymerase inhibitors |
WO2010135520A1 (en) * | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
JP2013501068A (en) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | Macrocyclic serine protease inhibitor |
CN106117213B (en) | 2009-10-26 | 2022-03-18 | 西格诺药品有限公司 | Heteroaryl compounds and methods for their synthesis and purification |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
AU2010333656B2 (en) | 2009-12-18 | 2015-08-27 | Boehringer Ingelheim International Gmbh | HCV combination therapy |
TW201136942A (en) | 2009-12-18 | 2011-11-01 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
CL2011000716A1 (en) | 2010-03-31 | 2012-04-20 | Gilead Pharmasset Llc | Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection. |
JP5872539B2 (en) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | Purine nucleoside phosphoramidate |
PL3290428T3 (en) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
JP2013523765A (en) | 2010-04-01 | 2013-06-17 | イデニク プハルマセウティカルス,インコーポレイテッド | Compounds and pharmaceutical compositions for the treatment of viral infections |
KR101879887B1 (en) * | 2010-09-20 | 2018-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
TW201300106A (en) | 2010-11-09 | 2013-01-01 | Hoffmann La Roche | Pharmaceutical compositions for treating HCV infections |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
WO2012087596A1 (en) * | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Combinations for treating hcv |
AR085352A1 (en) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS |
CN103842369A (en) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US9150603B2 (en) | 2011-04-13 | 2015-10-06 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
KR20140019832A (en) | 2011-04-13 | 2014-02-17 | 길리애드 사이언시즈, 인코포레이티드 | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
BR112013026345A2 (en) * | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | compound, pharmaceutical composition, use of a compound, and method for treating an hcv infected patient |
US20130018011A1 (en) * | 2011-06-10 | 2013-01-17 | Hassan Javanbakht | Method of treating dengue fever |
WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
AR088441A1 (en) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
ES2751921T3 (en) | 2011-10-19 | 2020-04-02 | Signal Pharm Llc | Cancer treatment with TOR kinase inhibitors |
EA201490837A1 (en) | 2011-10-21 | 2014-11-28 | Эббви Инк. | METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
DE112012003457T5 (en) | 2011-10-21 | 2015-03-12 | Abbvie Inc. | Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV) |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
CA3131037A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
CA3125862A1 (en) | 2011-12-02 | 2013-06-06 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
WO2013090420A2 (en) * | 2011-12-12 | 2013-06-20 | Catabasis Pharmaceuticals, Inc. | Fatty acid antiviral conjugates and their uses |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
MD20140094A2 (en) | 2012-02-14 | 2015-03-31 | University Of Georgia Research Foundation, Inc. | Spiro [2.4]heptanes for treatment of Flaviviridae infections |
US9375443B2 (en) | 2012-02-24 | 2016-06-28 | Signal Pharmaceuticals, Llc | Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
PE20150132A1 (en) | 2012-05-22 | 2015-02-14 | Idenix Pharmaceuticals Inc | D-AMINO ACID COMPOUNDS FOR HEPATIC DISEASE |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
EA201590006A1 (en) * | 2012-06-12 | 2015-05-29 | Ф. Хоффманн-Ля Рош Аг | COMBINATION OF THERAPEUTIC TOOLS FOR THE TREATMENT OF INFECTION CAUSED BY THE HEPATITIS VIRUS C |
WO2014047117A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
CA2887578A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharamaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
AR092959A1 (en) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | DERIVATIVES OF NUCLEOSIDS 2-METHYL SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
CN103804417B (en) * | 2012-11-13 | 2017-09-19 | 北京美倍他药物研究有限公司 | Anti-hepatic-B virus medicine |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
EP2938624A1 (en) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
CA2891125A1 (en) | 2012-11-19 | 2014-05-22 | Merck Sharp & Dohme Corp. | 2 -alkynyl substituted nucleoside derivatives for treating viral diseases |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
AR094494A1 (en) | 2013-01-16 | 2015-08-05 | Signal Pharm Llc | REPLACED PIRROLOPIRIMIDINS, THEIR COMPOSITIONS, AND THEIR TREATMENT METHODS |
MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121416A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
KR20150131045A (en) * | 2013-03-14 | 2015-11-24 | 키메로켐 엘엘씨 | Synthetic polymers containing amino acid side chains |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
TWI674897B (en) | 2013-04-17 | 2019-10-21 | 美商標誌製藥公司 | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
MX2015014599A (en) | 2013-04-17 | 2016-03-03 | Signal Pharm Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer. |
UA119538C2 (en) | 2013-04-17 | 2019-07-10 | Сігнал Фармасьютікалз, Елелсі | Treatment of cancer with dihydropyrazino-pyrazines |
ES2744198T3 (en) | 2013-04-17 | 2020-02-24 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use related to 1-ethyl-7- (2-methyl-6- (1H-1,2,4-triazol-3-yl) pyridin-3-yl) -3, 4 dihydropyrazine [2,3-b] pyrazin-2 (1H) -one |
CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
KR102221029B1 (en) | 2013-04-17 | 2021-02-26 | 시그날 파마소티칼 엘엘씨 | Treatment of cancer with dihydropyrazino-pyrazines |
EP2986319A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
MA46490A1 (en) * | 2013-05-16 | 2021-04-30 | Riboscience Llc | Substituted 4'- fluoro-2 '- methyl nucleoside derivatives |
NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
US9765107B2 (en) | 2013-06-18 | 2017-09-19 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
SG11201602595TA (en) | 2013-10-11 | 2016-04-28 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
US20170198005A1 (en) | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
CN114404427A (en) | 2014-02-13 | 2022-04-29 | 配体药物公司 | Prodrug compound and use thereof |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
CN104926902A (en) * | 2014-03-17 | 2015-09-23 | 张容霞 | 2'-substituted-2,2'-dehydrated uridine or 2'-substituted-2,2'-dehydrated cytidine compound and preparation method and use thereof |
WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
JP2017514806A (en) | 2014-04-16 | 2017-06-08 | シグナル ファーマシューティカルズ,エルエルシー | Methods of treating cancer using TOR kinase inhibitor combination therapy |
EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US10432742B2 (en) | 2014-06-06 | 2019-10-01 | Google Llc | Proactive environment-based chat information system |
CN106687118A (en) | 2014-07-02 | 2017-05-17 | 配体药物公司 | Prodrug compounds and uses thereof |
KR20170024120A (en) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
US10526363B2 (en) | 2014-08-15 | 2020-01-07 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CN104327138B (en) * | 2014-10-21 | 2017-05-10 | 齐鲁制药有限公司 | Preparation method of PSI-7977 intermediate compound |
EP3212597A1 (en) * | 2014-10-31 | 2017-09-06 | Sandoz AG | Improved fluorination process |
WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
EP3265102A4 (en) * | 2015-03-06 | 2018-12-05 | ATEA Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
WO2016160646A1 (en) | 2015-04-02 | 2016-10-06 | Merck Sharp & Dohme Corp. | Process for making phosphoramidate protected nucleoside compounds |
WO2016182935A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182934A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182939A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182936A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182937A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2017040766A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral tetrahydrofurane derivatives |
EA201892448A1 (en) * | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS |
CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017205078A1 (en) | 2016-05-27 | 2017-11-30 | Gilead Sciences, Inc. | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
KR20190043602A (en) | 2016-09-07 | 2019-04-26 | 아테아 파마슈티컬즈, 인크. | 2'-substituted-N6-substituted purine nucleotides for the treatment of RNA viruses |
SG11201906163TA (en) * | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
BR112019027402A2 (en) | 2017-06-22 | 2020-07-07 | Celgene Corporation | treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus |
CN111194217B (en) | 2017-09-21 | 2024-01-12 | 里伯赛恩斯有限责任公司 | 4 '-fluoro-2' -methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
CN112351799A (en) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | Treatment of HCV infected patients with cirrhosis |
WO2020007070A1 (en) * | 2018-07-02 | 2020-01-09 | 河南真实生物科技有限公司 | Crystal form, preparation method, and application of 4'-substituted nucleoside |
EP3860591A4 (en) * | 2018-10-04 | 2022-06-01 | Octagon Therapeutics Inc. | Pre-activated nucleoside impdh inhibitors as anti-infective drugs |
KR101970963B1 (en) | 2018-12-19 | 2019-04-23 | 주식회사 엠디헬스케어 | DNA aptamer binding specifically to yellow fever virus envelope protein domain III (YFV EDIII) and uses thereof |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CN111363712B (en) * | 2020-03-23 | 2020-11-03 | 华东师范大学 | Genetic engineering strain for expressing D structural domain fusion protein of microtubule beta subunit and protein A and construction method thereof |
EP4208549A1 (en) * | 2020-09-04 | 2023-07-12 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030060400A1 (en) * | 2000-05-26 | 2003-03-27 | Lacolla Paulo | Methods and compositions for treating flaviviruses and pestiviruses |
Family Cites Families (253)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US29835A (en) | 1860-08-28 | Surveyor s instrument | ||
CA1316A (en) | 1872-01-20 | J.P. Cleveland | Improvements in boilers for heating sap and other liquids | |
CA100197A (en) | 1906-05-01 | 1906-07-24 | Cecil Beckwith | Apparatus for placing pneumatic tires on wheel rims |
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
FR2562543B1 (en) | 1984-04-10 | 1987-09-25 | Elf Aquitaine | NOVEL CYCLIC PHOSPHONITES, THEIR PREPARATION AND APPLICATIONS |
NL8403224A (en) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS. |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
IL85778A0 (en) | 1987-03-20 | 1988-09-30 | Bristol Myers Co | Production of 2',3'-dideoxynucleosides and certain such novel compounds |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
AU2526188A (en) | 1987-09-22 | 1989-04-18 | Regents Of The University Of California, The | Liposomal nucleoside analogues for treating aids |
DE3825158C1 (en) | 1988-07-07 | 1989-06-01 | Franz Bisping Gmbh & Co, 4400 Muenster, De | |
SE8802687D0 (en) | 1988-07-20 | 1988-07-20 | Astra Ab | NUCLEOSIDE DERIVATIVES |
US5616702A (en) | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5075225A (en) | 1989-04-06 | 1991-12-24 | The Texas A&M University System | Process for the enzymatic synthesis of nucleosides |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
DE3924424A1 (en) | 1989-07-24 | 1991-01-31 | Boehringer Mannheim Gmbh | NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINAL PRODUCT AND THEIR USE IN THE SEQUENCING OF NUCLEIC ACID |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
ES2152922T3 (en) | 1990-04-06 | 2001-02-16 | Genelabs Tech Inc | HEPATITIS VIRUS VIRUS EPITHOPES. |
WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
AU7623991A (en) | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
JP3347723B2 (en) | 1990-06-13 | 2002-11-20 | グラツィエル,アーノルド | Phosphorus-containing prodrug |
US5272152A (en) | 1990-07-02 | 1993-12-21 | E. R. Squibb & Sons, Inc. | Purinyl and pyrimidinyl tetrahydrofurans |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
JPH07500573A (en) | 1991-07-12 | 1995-01-19 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | Antiviral liponucleosides: treatment of hepatitis B |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
TW224053B (en) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5405598A (en) | 1992-02-24 | 1995-04-11 | Schinazi; Raymond F. | Sensitizing agents for use in boron neutron capture therapy |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
HU214980B (en) | 1992-09-01 | 1998-08-28 | Eli Lilly And Co. | A process for anomerizing nucleosides |
GB9226729D0 (en) | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
ATE181557T1 (en) | 1993-02-24 | 1999-07-15 | Jui H Wang | COMPOSITIONS AND METHODS OF APPLYING REACTIVE ANTIVIRAL POLYMERS |
CA2162574A1 (en) | 1993-05-12 | 1994-11-24 | Karl Y. Hostetler | Acyclovir derivatives for topical use |
TW374087B (en) | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
AU688344B2 (en) | 1993-07-19 | 1998-03-12 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Hepatitis C virus proliferation inhibitor |
US7375198B2 (en) * | 1993-10-26 | 2008-05-20 | Affymetrix, Inc. | Modified nucleic acid probes |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5711944A (en) | 1993-11-10 | 1998-01-27 | Enzon, Inc. | Interferon polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
WO1995024185A1 (en) | 1994-03-11 | 1995-09-14 | Isis Pharmaceuticals, Inc. | Novel pyrimidine nucleosides |
DE4447588C2 (en) | 1994-05-03 | 1997-11-20 | Omer Osama Dr Dr Med | Treatment of herpes and hepatitis virus infections and bronchitis |
JPH10501809A (en) | 1994-06-22 | 1998-02-17 | ネクスター ファーマスーティカルズ,インコーポレイテッド | Novel method for producing known and novel 2'-nucleosides by intramolecular nucleophilic substitution |
DE4432623A1 (en) | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Process for bleaching aqueous surfactant solutions |
US5559101A (en) | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5703058A (en) | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
JP3786447B2 (en) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Preventive and therapeutic agent for hepatitis C |
DE19514523A1 (en) | 1995-04-12 | 1996-10-17 | Schering Ag | New cytosine and cytidine derivatives |
EP0859833B1 (en) | 1995-09-27 | 2006-03-01 | Emory University | Recombinant hepatitis c virus rna replicase |
CN1201463A (en) | 1995-11-02 | 1998-12-09 | 株式会社钟根堂 | Novel nucleoside derivatives and process for preparing same |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5767097A (en) | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
GB9602028D0 (en) | 1996-02-01 | 1996-04-03 | Amersham Int Plc | Nucleoside analogues |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
EP0914421A2 (en) | 1996-02-29 | 1999-05-12 | Immusol, Inc. | Hepatitis c virus ribozymes |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
GB9609932D0 (en) | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US5837257A (en) | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
US6049333A (en) * | 1996-09-03 | 2000-04-11 | Time Warner Entertainment Company, L.P. | System and method for providing an event database in a telecasting system |
JP3927630B2 (en) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Preventive and therapeutic agents for viral infections |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
EP0934325B1 (en) | 1996-10-09 | 2004-07-14 | Pharmasset, Ltd. | Mycophenolic bisphosphonate compounds |
US6455690B1 (en) | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
US6509320B1 (en) | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
DE69729887T2 (en) | 1996-10-16 | 2005-07-28 | ICN Pharmaceuticals, Inc., Costa Mesa | Purine L nucleosides, analogs and their use |
DE69721339T2 (en) | 1996-10-16 | 2004-01-22 | Ribapharm, Inc., Costa Mesa | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND THEIR APPLICATIONS |
IL129407A0 (en) | 1996-10-18 | 2000-02-17 | Vertex Pharma | Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
IL119833A (en) | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
US20020127371A1 (en) * | 2001-03-06 | 2002-09-12 | Weder Donald E. | Decorative elements provided with a circular or crimped configuration at point of sale or point of use |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
PL193237B1 (en) | 1997-06-30 | 2007-01-31 | Merz Pharma Gmbh & Co Kgaa | Derivatives of 1-aminoalkyl cyclohexane as antagonists of nmda receptor |
AU757072B2 (en) | 1997-08-11 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
DE69810822T2 (en) | 1997-09-21 | 2003-11-20 | Schering Corp | Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection |
US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
WO1999023104A2 (en) | 1997-10-30 | 1999-05-14 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services | Antitumour uridine analogues |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
ES2276515T3 (en) | 1998-02-25 | 2007-06-16 | Emory University | 2'-FLUORONUCLEOSIDS. |
US6787305B1 (en) | 1998-03-13 | 2004-09-07 | Invitrogen Corporation | Compositions and methods for enhanced synthesis of nucleic acid molecules |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
KR100694345B1 (en) | 1998-05-15 | 2007-03-12 | 쉐링 코포레이션 | Pharmaceutical composition comprising ribavirin and interferon alpha for antiviral treatment naive patients having chronic hepatitis c infection |
ES2251196T3 (en) | 1998-06-08 | 2006-04-16 | F. Hoffmann-La Roche Ag | USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
CN100387237C (en) | 1998-08-10 | 2008-05-14 | 艾丹尼克斯(开曼)有限公司 | Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B |
CN1245808A (en) | 1998-08-21 | 2000-03-01 | 同济医科大学附属同济医院 | Compound resisting hepatitis virus and its preparation method and its application in pharmaceutical technology |
FR2784892B1 (en) | 1998-10-23 | 2001-04-06 | Smith & Nephew Kinetec Sa | FOLDABLE PASSIVE MOBILIZATION BRACKET FOR LOWER MEMBER |
EP1140143A2 (en) | 1998-12-18 | 2001-10-10 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
TR200601784T2 (en) * | 1999-11-12 | 2007-01-22 | Pharmasset Ltd. | Synthesis of 2'-deoxy-L-nucleosides |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
AU2001235278A1 (en) | 2000-02-18 | 2001-08-27 | Shire Biochem Inc | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
EP1284741B1 (en) | 2000-04-13 | 2008-11-19 | Pharmasset, Inc. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections |
US6924270B2 (en) | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
TR200402565T4 (en) | 2000-05-26 | 2004-12-21 | Idenix (Cayman) Limited | Use of ß-L-2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
FR2810322B1 (en) * | 2000-06-14 | 2006-11-10 | Pasteur Institut | COMBINATORY PRODUCTION OF NUCLEOTIDE AND NUCLEOTIDE ANALOGUES (XiTP) |
MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
WO2002008251A2 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
AR034127A1 (en) | 2000-07-21 | 2004-02-04 | Schering Corp | IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
AR039558A1 (en) * | 2000-08-21 | 2005-02-23 | Inspire Pharmaceuticals Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US6897201B2 (en) | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
SV2003000617A (en) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
EP2180064A3 (en) | 2000-10-18 | 2010-08-11 | Pharmasset, Inc. | Multiplex quantification of nucleic acids in diseased cells |
HUP0301444A3 (en) | 2000-10-18 | 2007-05-29 | Schering Corp | The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection |
KR20090089922A (en) | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
US6555677B2 (en) | 2000-10-31 | 2003-04-29 | Merck & Co., Inc. | Phase transfer catalyzed glycosidation of an indolocarbazole |
ATE327246T1 (en) | 2000-11-20 | 2006-06-15 | Bristol Myers Squibb Co | HEPATITIS C TRIPEPTIDE INHIBITORS |
DE20019797U1 (en) | 2000-11-21 | 2001-04-05 | Mala Verschlussysteme Gmbh | Sealing cap |
AU2002236591B2 (en) | 2000-12-12 | 2005-07-14 | Schering Corporation | Diaryl peptides as NS3-serine protease inhibitors of hepatits C virus |
WO2002048157A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
BR0116223A (en) | 2000-12-15 | 2006-01-31 | Triangle Pharmaceuticals Inc | Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor |
BR0116221A (en) | 2000-12-15 | 2005-09-13 | Pharmasset Ltd | Antiviral agents for treatment of flaviviridae infections |
US6750396B2 (en) | 2000-12-15 | 2004-06-15 | Di/Dt, Inc. | I-channel surface-mount connector |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
JP3914156B2 (en) * | 2001-01-22 | 2007-05-16 | メルク エンド カムパニー インコーポレーテッド | Nucleoside derivatives as RNA-dependent RNA viral polymerase inhibitors |
WO2002070533A2 (en) | 2001-03-01 | 2002-09-12 | Pharmasset Ltd. | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
WO2003022861A1 (en) | 2001-09-13 | 2003-03-20 | Bristol-Myers Squibb Company | Process for the preparation of rebeccamycin and analogs thereof |
WO2003024461A1 (en) | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
AU2002330154A1 (en) * | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
GB0129945D0 (en) | 2001-12-13 | 2002-02-06 | Mrc Technology Ltd | Chemical compounds |
CN100560073C (en) | 2001-12-14 | 2009-11-18 | 法玛塞特公司 | The N that is used for the treatment of viral infection 4-acyl group cytidine |
WO2003051899A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
AU2002360697B2 (en) | 2001-12-20 | 2009-04-23 | Beth Israel Deaconess Medical Center | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation |
WO2003055896A2 (en) | 2001-12-21 | 2003-07-10 | Micrologix Biotech Inc. | Anti-viral 7-deaza l-nucleosides |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
EP1476169B1 (en) | 2002-02-13 | 2013-03-20 | Merck Sharp & Dohme Corp. | Inhibiting orthopoxvirus replication with nucleoside compounds |
CA2477741A1 (en) * | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
AU2003213628A1 (en) * | 2002-02-28 | 2003-09-16 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
WO2003100017A2 (en) * | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
JP2005533777A (en) | 2002-06-17 | 2005-11-10 | メルク エンド カムパニー インコーポレーテッド | Carbocyclic nucleoside analogs as RNA antiviral agents |
AU2003248708A1 (en) | 2002-06-17 | 2003-12-31 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
WO2004000858A2 (en) | 2002-06-21 | 2003-12-31 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003269892A1 (en) | 2002-06-27 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
RS113904A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CN1761677A (en) | 2002-06-28 | 2006-04-19 | 埃迪尼克斯(开曼)有限公司 | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
PL374831A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
JP5087211B2 (en) | 2002-06-28 | 2012-12-05 | イデニクス(ケイマン)リミテツド | 2 'and 3'-nucleoside prodrugs for the treatment of flavivirus infection |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
CA2491673A1 (en) * | 2002-07-08 | 2004-01-15 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |
AU2003269902A1 (en) | 2002-07-16 | 2004-02-02 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003261237A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases |
AU2003256619A1 (en) * | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
CA2492607A1 (en) * | 2002-07-25 | 2004-02-05 | Micrologix Biotech Inc. | Anti-viral 7-deaza d-nucleosides and uses thereof |
EP1545545A4 (en) | 2002-08-01 | 2008-09-03 | Pharmasset Inc | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
EP1534255B1 (en) | 2002-08-06 | 2011-01-19 | Pharmasset, Inc. | Processes for preparing 1,3-dioxolane nucleosides |
US7186700B2 (en) * | 2002-09-13 | 2007-03-06 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
WO2004084453A2 (en) | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES |
US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7168002B2 (en) | 2003-04-25 | 2007-01-23 | International Business Machines Corporation | Preservation of error data on a diskless platform |
CA2522845A1 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
AU2004233989A1 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
JP5069463B2 (en) | 2003-04-25 | 2012-11-07 | ギリアード サイエンシーズ, インコーポレイテッド | Antiviral phosphonate analogues |
US20050261237A1 (en) | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
US7452901B2 (en) * | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
EP1656093A2 (en) | 2003-05-14 | 2006-05-17 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
KR100883703B1 (en) | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | Modified fluorinated nucleoside analogues |
EP1644479A4 (en) | 2003-06-16 | 2008-04-23 | Mark W Grinstaff | Functional synthetic molecules and macromolecules for gene delivery |
DE10331239A1 (en) | 2003-07-10 | 2005-02-03 | Robert Bosch Gmbh | Monitoring electronics for an electric motor and method for monitoring an electric motor |
US7073213B2 (en) | 2003-07-18 | 2006-07-11 | Carlos Duarte | Upright hinge for spa cover |
GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
JP2007501185A (en) | 2003-07-25 | 2007-01-25 | イデニクス(ケイマン)リミテツド | Purine nucleoside analogues for treating flavivirus related diseases including hepatitis C |
EP1660511B1 (en) | 2003-08-27 | 2010-11-03 | Biota Scientific Management Pty. Ltd. | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
AU2005208887B2 (en) | 2004-01-28 | 2010-02-25 | Merck Sharp & Dohme Corp. | Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity |
WO2005087788A2 (en) | 2004-03-04 | 2005-09-22 | The Regents Of The University Of California | Methods for preparation of nucleoside phosphonate esters |
EP1912643A2 (en) * | 2004-06-23 | 2008-04-23 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
EP2348029A1 (en) | 2004-07-21 | 2011-07-27 | Pharmasset, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
BRPI0512104A8 (en) | 2004-07-21 | 2018-04-24 | Gilead Pharmasset Llc | preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and their derivatives |
CN101023094B (en) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
WO2006029081A2 (en) | 2004-09-02 | 2006-03-16 | Neopharm, Inc. | Nucleoside-lipid conjugates, their method of preparation and uses thereof |
SI3109244T1 (en) | 2004-09-14 | 2019-06-28 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
EP1804811A4 (en) | 2004-09-24 | 2011-04-27 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
AU2005317081A1 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection |
GB0427123D0 (en) | 2004-12-11 | 2005-01-12 | Apv Systems Ltd | Food item coating apparatus and method |
CN1827362B (en) | 2005-03-03 | 2012-01-25 | 优泊公司 | Tag for forming in mold and formed product using same |
US20070004299A1 (en) | 2005-06-17 | 2007-01-04 | Toray Plastics (America), Inc. Lumirror Division | Barrier film with enhanced adhesive properties |
DE102005030372A1 (en) | 2005-06-29 | 2007-01-04 | Infineon Technologies Ag | Apparatus and method for controlling the threshold voltage of a transistor, in particular a transistor of a sense amplifier of a semiconductor memory device |
US7573967B2 (en) | 2005-07-01 | 2009-08-11 | Slt Logic Llc | Input threshold adjustment in a synchronous data sampling circuit |
US7693225B2 (en) | 2005-07-21 | 2010-04-06 | Realtek Semiconductor Corp. | Inter-symbol and inter-carrier interference canceller for multi-carrier modulation receivers |
CN102924549A (en) | 2005-09-26 | 2013-02-13 | 吉利德制药有限责任公司 | Modified 4'-nucleosides as antiviral agents |
UA91255C2 (en) | 2005-12-09 | 2010-07-12 | Ф. Хоффманн-Ля Рош Аг | Antiviral nucleosides |
DE102005061285A1 (en) | 2005-12-20 | 2007-06-21 | Lemförder Electronic GmbH | Selection device for shifting vehicle gearbox, has control unit rotatable about rotational axis, and actuator delivering turning moment to shaft, where shaft extends between rotation angle detecting device and control unit along axis |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
MX2009003795A (en) | 2006-10-10 | 2009-06-18 | Pharmasset Inc | Preparation of nucleosides ribofuranosyl pyrimidines. |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8286696B2 (en) | 2007-06-22 | 2012-10-16 | The Boeing Company | Mechanically actuated thermal switch |
CN201113124Y (en) | 2007-07-10 | 2008-09-10 | 富士康(昆山)电脑接插件有限公司 | Battery connector |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
WO2009086192A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
AR075584A1 (en) | 2009-02-27 | 2011-04-20 | Intermune Inc | THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND. |
US8088368B2 (en) | 2009-05-13 | 2012-01-03 | Gilead Sciences, Inc. | Antiviral compounds |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
CL2011000716A1 (en) | 2010-03-31 | 2012-04-20 | Gilead Pharmasset Llc | Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection. |
SG190785A1 (en) | 2010-11-17 | 2013-07-31 | Gilead Sciences Inc | Antiviral compounds |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
US8788437B2 (en) | 2011-07-28 | 2014-07-22 | Quova, Inc. | System and method for implementing a learning model for predicting the geographic location of an internet protocol address |
HUE036588T2 (en) | 2011-09-16 | 2018-07-30 | Gilead Pharmasset Llc | Methods for treating hcv |
MD4521C1 (en) | 2011-11-16 | 2018-05-31 | Gilead Pharmasset Llc. | Antiviral compounds based on condensed imidazolyl-dihydroisochromeno-naphthoimidazols |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
US8969588B2 (en) | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
AR094466A1 (en) | 2013-01-14 | 2015-08-05 | Hoffmann La Roche | PROCESS FOR OBTAINING A FLUORLACTONE DERIVATIVE |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
TW201609785A (en) | 2013-12-23 | 2016-03-16 | 吉李德製藥公司 | Solid forms of an antiviral compound |
TW202014413A (en) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | Processes for preparing antiviral compounds |
TWI721947B (en) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | Solid forms of an antiviral compound |
-
2004
- 2004-04-21 KR KR1020057022965A patent/KR100883703B1/en active IP Right Grant
- 2004-04-21 NZ NZ543867A patent/NZ543867A/en unknown
- 2004-04-21 ES ES19160413T patent/ES2906207T3/en active Active
- 2004-04-21 PT PT04775900T patent/PT1633766T/en unknown
- 2004-04-21 CA CA2734066A patent/CA2734066A1/en not_active Abandoned
- 2004-04-21 WO PCT/US2004/012472 patent/WO2005003147A2/en active Application Filing
- 2004-04-21 SI SI200432518T patent/SI3521297T1/en unknown
- 2004-04-21 CA CA2734055A patent/CA2734055A1/en not_active Abandoned
- 2004-04-21 BR BRPI0419345A patent/BRPI0419345B8/en active IP Right Grant
- 2004-04-21 DK DK13152340.9T patent/DK2604620T3/en active
- 2004-04-21 BR BR122018015050-5A patent/BR122018015050B1/en active IP Right Grant
- 2004-04-21 TR TR2019/06767T patent/TR201906767T4/en unknown
- 2004-04-21 MX MXPA05012788A patent/MXPA05012788A/en active IP Right Grant
- 2004-04-21 PT PT131523409T patent/PT2604620T/en unknown
- 2004-04-21 BR BRPI0410846A patent/BRPI0410846B8/en active IP Right Grant
- 2004-04-21 CA CA2527657A patent/CA2527657C/en active Active
- 2004-04-21 EP EP19160413.1A patent/EP3521297B1/en active Active
- 2004-04-21 ES ES04775900T patent/ES2726998T3/en active Active
- 2004-04-21 US US10/828,753 patent/US7429572B2/en active Active
- 2004-04-21 EP EP21216654.0A patent/EP4032897A1/en active Pending
- 2004-04-21 PL PL19160413T patent/PL3521297T3/en unknown
- 2004-04-21 AU AU2004253860A patent/AU2004253860B2/en active Active
- 2004-04-21 SI SI200432464T patent/SI1633766T1/en unknown
- 2004-04-21 EP EP11157942A patent/EP2345658A1/en not_active Withdrawn
- 2004-04-21 ES ES13152340.9T patent/ES2586668T3/en active Active
- 2004-04-21 JP JP2006513231A patent/JP4958158B2/en active Active
- 2004-04-21 EP EP11157832A patent/EP2345657A1/en not_active Withdrawn
- 2004-04-21 HU HUE13152340A patent/HUE029877T2/en unknown
- 2004-04-21 PL PL04775900T patent/PL1633766T3/en unknown
- 2004-04-21 CA CA2733842A patent/CA2733842A1/en not_active Abandoned
- 2004-04-21 EP EP11157939A patent/EP2345661A1/en not_active Withdrawn
- 2004-04-21 PT PT191604131T patent/PT3521297T/en unknown
- 2004-04-21 PL PL13152340.9T patent/PL2604620T3/en unknown
- 2004-04-21 LT LTEP13152340.9T patent/LT2604620T/en unknown
- 2004-04-21 EP EP11157954A patent/EP2345659A1/en not_active Withdrawn
- 2004-04-21 SI SI200432330A patent/SI2604620T1/en unknown
- 2004-04-21 EP EP13152340.9A patent/EP2604620B1/en active Active
- 2004-04-21 RU RU2005141176/04A patent/RU2358979C2/en active
- 2004-04-21 CN CNB2004800191484A patent/CN100503628C/en active Active
- 2004-04-21 CA CA2734052A patent/CA2734052A1/en not_active Abandoned
- 2004-04-21 EP EP04775900.6A patent/EP1633766B1/en not_active Revoked
- 2004-04-28 MY MYPI20041584A patent/MY138477A/en unknown
- 2004-05-07 TW TW093112913A patent/TWI333956B/en active
- 2004-05-27 AR ARP040101821A patent/AR044566A1/en not_active Application Discontinuation
-
2005
- 2005-11-24 ZA ZA200509521A patent/ZA200509521B/en unknown
- 2005-11-29 IL IL172259A patent/IL172259A/en active IP Right Grant
- 2005-12-05 CO CO05123296A patent/CO5660270A2/en active IP Right Grant
- 2005-12-28 NO NO20056221A patent/NO333700B1/en unknown
-
2007
- 2007-09-12 US US11/854,218 patent/US10287311B2/en active Active
-
2008
- 2008-06-19 US US12/142,536 patent/US20090004135A1/en not_active Abandoned
- 2008-06-19 US US12/142,554 patent/US20080253995A1/en not_active Abandoned
- 2008-09-29 US US12/240,342 patent/US20090036666A1/en not_active Abandoned
-
2010
- 2010-09-09 US US12/878,262 patent/US8415322B2/en active Active
- 2010-12-29 IL IL210367A patent/IL210367A0/en active IP Right Grant
-
2011
- 2011-04-11 NO NO20110548A patent/NO20110548L/en unknown
- 2011-04-11 NO NO20110550A patent/NO20110550L/en not_active Application Discontinuation
- 2011-04-11 NO NO20110549A patent/NO20110549L/en not_active Application Discontinuation
- 2011-04-11 NO NO20110547A patent/NO20110547L/en not_active Application Discontinuation
- 2011-04-14 JP JP2011090084A patent/JP2011201882A/en not_active Withdrawn
- 2011-04-14 JP JP2011090062A patent/JP2011190263A/en not_active Withdrawn
- 2011-04-14 JP JP2011090076A patent/JP2011190264A/en not_active Withdrawn
- 2011-04-14 JP JP2011090054A patent/JP5266357B2/en active Active
- 2011-06-30 AR ARP110102356A patent/AR082066A2/en unknown
- 2011-06-30 AR ARP110102354A patent/AR082064A2/en unknown
- 2011-06-30 AR ARP110102357A patent/AR082067A2/en unknown
- 2011-06-30 AR ARP110102358A patent/AR082068A2/en unknown
-
2012
- 2012-06-07 US US13/491,441 patent/US20120245335A1/en not_active Abandoned
-
2016
- 2016-07-14 HR HRP20160873TT patent/HRP20160873T1/en unknown
- 2016-09-19 CY CY20161100927T patent/CY1118020T1/en unknown
- 2016-12-21 HU HUS1600062C patent/HUS1600062I1/en unknown
- 2016-12-21 LT LTPA2016046C patent/LTPA2016046I1/en unknown
- 2016-12-22 CY CY2016052C patent/CY2016052I2/en unknown
-
2018
- 2018-06-26 AR ARP180101768A patent/AR114929A2/en not_active Application Discontinuation
- 2018-10-17 US US16/162,634 patent/US20190315792A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030060400A1 (en) * | 2000-05-26 | 2003-03-27 | Lacolla Paulo | Methods and compositions for treating flaviviruses and pestiviruses |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299038B2 (en) | 2000-05-23 | 2012-10-30 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US8957046B2 (en) | 2007-03-30 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US9045520B2 (en) | 2008-12-23 | 2015-06-02 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US9549941B2 (en) | 2011-11-29 | 2017-01-24 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
JP7196054B2 (en) | 2012-12-21 | 2022-12-26 | ヤンセン バイオファーマ インク. | Substituted Nucleosides, Substituted Nucleotides and Their Analogues |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005003147A3 (en) | Modified fluorinated nucleoside analogues | |
TW200500373A (en) | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
EG24465A (en) | Nucleoside derivatives as inhibitors of RNA dependent RNA viral polymerase | |
DK2251015T3 (en) | Modified nucleotides to treat viral infections and abnormal cell proliferation | |
BR0309581A (en) | Nucleoside derivatives for treatment of hepatitis c virus infection | |
RS20120201A3 (en) | Methods and compositions for hepatitis c virus treatment | |
WO2003062255A3 (en) | Sugar modified nucleosides as viral replication inhibitors | |
WO2006063281A3 (en) | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | |
WO2004007512A3 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
WO2004003138A3 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
EP1572097A4 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
AP2005003213A0 (en) | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. | |
WO2005009418A3 (en) | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c | |
AU2002252183A1 (en) | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases | |
NO20025600D0 (en) | Methods and compositions for the treatment of flaviviruses and pestiviruses | |
WO2004003000A3 (en) | 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections | |
PA8588501A1 (en) | NUCLEOSID ANTIVIRAL DERIVATIVES | |
WO2004032872A3 (en) | Epo D + 5-FU/GEMCITABINE | |
DE69500618D1 (en) | OLIGONUCLEOTIDES WITH EFFECT AGAINST THE RESPIRATORY SYNCYTIAL VIRUS | |
MXPA04004621A (en) | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases. | |
WO2002087600A8 (en) | Use of phyllanthus constituents for treating or preventing infections caused by hepatit | |
TH79569B (en) | Analogs of modified fluorinated nucleosides. | |
CY1113987T1 (en) | MODIFIED nucleosides for the treatment of viral infections and abnormal cell proliferation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480019148.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004253860 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/09521 Country of ref document: ZA Ref document number: 200509521 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/012788 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 172259 Country of ref document: IL Ref document number: 12005502136 Country of ref document: PH Ref document number: 2527657 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057022965 Country of ref document: KR Ref document number: 543867 Country of ref document: NZ Ref document number: 2006513231 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05123296 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6087/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004775900 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005141176 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004253860 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057022965 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004775900 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0410846 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 210367 Country of ref document: IL |